European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and l
| Condition(s) | Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis, Pulmonary Eosinophilia, Pulmonary Fibrosis, Respiratory Distress Syndrome, Newborn, Child |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes |
| Who can participate | Inclusion Criteria: * all children with suspected or * verified diagnosis of ILD or * masquerading as ILD and * those with rare localized parenchymal lung diseases Exclusion Criteria: * other indication as inclusion criteria |
| Sex | All |
| Lead sponsor | Matthias Griese |
| Locations | Hanover, Lower Saxony, Germany; Ankara, Sihhiye, Turkey (Türkiye); Edinburgh, United Kingdom |
| Start date | 2013-12 |
| NCT ID | NCT02852928 |
| Official listing | https://clinicaltrials.gov/study/NCT02852928 |